As we kick off an exciting 2013 for biotech investors, all eyes are on Amarin's (AMRN 2.28%) Vascepa launch. This is the company's first foray into the triglyceride-lowering space, and, as investors continue to speculate on whether it can successfully commercialize the drug, they may be forgetting about another opportunity. That, of course, is the ANCHOR indication.
In a recent presentation, Amarin's CEO suggested that the sNDA for this indication could be submitted as early as February. This expanded approval has the potential to unlock an enormous patient population -- but this isn't a guaranteed slam dunk.
In this video, health care analyst Max Macaluso discusses the potential pitfalls that Amarin could face in getting this indication approved.
